Navigation Links
Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
Date:9/4/2012

INDIANAPOLIS, Sept. 4, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IgG Antibody to herpes simplex virus (HSV) types 1 and 2 assays for use on cobas® modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection. 

"These are the first automated type-specific herpes tests available for integrated analyzer platforms, which will enable labs to integrate efficient herpes testing into their existing workflow," said Randy Pritchard, vice president of marketing at Roche Diagnostics Corporation. "The approval of the type-specific assays also means healthcare providers now have another tool to give them greater confidence in their diagnosis and overall patient care."

The addition of these tests further expands the company's infectious disease test portfolio for labs of all sizes. Roche currently offers the broadest test menu available on an integrated (chemistry and immunoassay) platform.

About the Tests
The Elecsys HSV-1 IgG and HSV-2 IgG assays are for the in-vitro qualitative determination of IgG class antibodies to HSV-1 and HSV-2 in human serum or plasma. The immunoassays are intended for use with Roche's electrochemiluminescence (ECL) technology, a highly sensitive light detection system that provides excellent low-end sensitivity and broad dynamic measuring ranges. The tests are approved for use on the Elecsys 2010, cobas e 411, cobas e 601, cobas e 602 and MODULAR ANALYTICS E170 analyzers.

About Herpes Simplex Virus
Herpes Simplex Virus Type 1 is mainly transmitted via social contacts during childhood and is generally prevalent in 70-90% of the population.  Herpes Simplex Virus Type 2 is usually transmitted sexually and has a prevalence of approximately 17-25% in the general population.  HSV Type 1 is most commonly associated with oral herpes, causing infections (sores) of the mouth and lips. HSV Type 2 is primarily associated with genital herpes. Type-specific HSV IgG detection is fundamental to helping healthcare providers manage patients and develop strategies to prevent transmission to partners and babies. 

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky

Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN

(317) 521-3966

todd.siesky@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Third Quarter Results
2. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
3. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
4. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
5. Roche announces FDA approval of HIV viral load test
6. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
7. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
8. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
9. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
10. China Botanic Receives New Patent on its Comprehensive Method to Enhance the Medicinal Value of Schisandra
11. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2020)... ... September 02, 2020 , ... Rigaku Analytical Devices , ... among industry professionals about successes and challenges of making changes to their organizations’ ... and will take place on October 15, 2020 at 10:00am PDT / ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... Cosmetics and Laser Surgery at the University of Rochester Medical Center, in Upstate ... SkinCare Physicians in Boston, with clinical faculty from the Harvard and Yale Departments ...
(Date:9/1/2020)... ... ... September is National Ovarian Cancer Awareness Month. Ovarian cancer is the 5th deadliest ... reproductive system. The American Cancer Society estimates that in 2020, about 22,000 women ... disease. Throughout the month of September, Women’s Excellence aims to increase understanding of ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... 31, 2020 , ... Want to get moving, break up your routine, and ... is thrilled to launch its fourth annual STEPtember campaign in the United States to ... everyone wherever they are at this moment — encouraging people to move in the ...
(Date:8/31/2020)... , ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to ... budgets and look for ways to trim the fat from our monthly expenses and put ... but it’s also important that you have a financial safety net in place in case ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... improve outcomes for patients with advanced heart failure, today announced that the company ... the amount of $555,358 from the National Heart, Lung, and Blood Institute of ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... ... a one-year subscription to a customized Lighthouse Health & Wellness mobile app and ... of this project. Motorola Solutions Foundation awards grants each year to organizations, such ...
(Date:8/28/2020)... ... August 28, 2020 , ... A July 27 ... individuals are at an increased risk of developing severe COVID-19 symptoms. The article ... however, because the same organ systems that the coronavirus attacks are already suffering ...
Breaking Medicine News(10 mins):